Ascendis Pharma A/S (ASND) Stock Score, Valuation & Financial Research
Ascendis Pharma A/S is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 49/100.
Quick answer for ASND
Ascendis Pharma A/S currently has a Wall Street Score of 49/100. The stored market price is $261.23. Its financial score is 30/100. Its valuation score is 93/100. These figures are a research snapshot, not a buy or sell recommendation.
What Ascendis Pharma A/S does
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Foun
ASND financial snapshot
- Wall Street Score:
- 49/100
- Current price:
- $261.23
- Market capitalization:
- $16.23B
- Revenue:
- $1.23B
- Net income:
- $878.5M
- Free cash flow:
- $50.7M
- Cash:
- $943.7M
- Total debt:
- $522.9M
- EPS:
- 14.06
- P/E ratio:
- 18.6x
- Financial score:
- 30/100
- Valuation score:
- 93/100
- Revenue score:
- 66/100
What stands out
- Reported year-over-year revenue growth is +0.5%.
- Free cash flow is $50.7M, showing positive cash generation.
- The balance sheet shows $943.7M of cash versus $522.9M of total debt, leaving more cash than debt.
- The current research record carries a severe debt stress warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 30/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-08.
How to research ASND
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.